# Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

> **NCT07023588** · PHASE2 · RECRUITING · sponsor: **Yehui Tan** · enrollment: 70 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07023588
- **Lead sponsor:** Yehui Tan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023588, "Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07023588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*